Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objectives: The objective of this study was to examine the association between the use of statins and the risk of newly diagnosed dementia in an elderly population. Design, setting and participants: Random samples of 1000 000 individuals covered by the National Health Insurance in Taiwan were included in the analysis. All participants were 65 years or older without dementia and either did or did not start treatment with statins from 1 August 1997 to 31 December 2010. Patients with established dementia before the start of treatment were excluded. Baseline characteristics were matched (by propensity score) in those who did and did not receive statins. Results: A total of 57 669 subjects were included in the analysis with approximately 12 years of follow‐up. Propensity score matching identified 2003 patients who received statins and another 2003 patients who did not with comparable baseline characteristics. Adjusted hazard ratios (HR s) for dementia were significantly inversely associated with total or daily equivalent statin dosage (total accumulated dose: HR s 0.829, 0.720 and 0.385 from T1 to T3 vs. control, P < 0.001 for trend; mean daily dose: HR s 0.667, 0.798 and 0.503 from T1 to T3 vs. control, P < 0.001). The results remained robust after propensity adjustment. Conclusion: Independent of traditional risk factors, there was a decrease in newly diagnosed cases of dementia in elderly patients who had received a high total or daily dose of statins. The more potent statins (e.g. atorvastatin and rosuvastatin) seemed to be particularly effective in the prevention of dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Relation of Plasma Lipids to Alzheimer Disease and Vascular Dementia
Reitz, C., Tang, M.-X., Luchsinger, J., & Mayeux, R. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.705 · Cited by 397
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393
Cited by
Olmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., Zambon, A., Catapano, A. L., & Casula, M. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab208 · Cited by 197
Wang, Y.-C., Tai, P.-A., Poly, T. N., Islam, M. M., Yang, H.-C., Wu, C.-C., & Li, Y.-C. (. (2018) · Behavioural Neurology · doi:10.1155/2018/5315098 · Cited by 115
Self-citationThe role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventions
Hunsberger, H. C., Pinky, P. D., Smith, W., Suppiramaniam, V., & Reed, M. N. (2019) · Neuronal Signaling · doi:10.1042/ns20180203 · Cited by 94
Adhikari, A., Tripathy, S., Chuzi, S., Peterson, J., & Stone, N. J. (2021) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.10.007 · Cited by 52
Rajan, K. B., Mcaninch, E. A., Wilson, R. S., Dhana, A., Evans-Lacko, S., & Evans, D. A. (2024) · Neurology · doi:10.1212/wnl.0000000000209168 · Cited by 34
Metadata
- Authors
- Wu, C. ‐., Yang, Y. ‐., Lin, T. ‐., Tsai, C. ‐., Hwang, J. ‐., Lin, J. ‐., Chen, P. ‐., Chiang, F. ‐., & Lin, L. ‐.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2014-05-21
- Volume
- 277
- Issue
- 3
- Pages
- 343-352
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2056017773
- Cited by
- 39
- References
- 3
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.